|
2024
|
Invention
|
Solid dispersion of myeloid kinome inhibitors and pharmaceutical composition comprising the same.... |
|
|
Invention
|
Combination formulation comprising sacubitril-valsartan and sglt-2 inhibitor having improved stab... |
|
|
Invention
|
Combination therapy of interleukin-2 analog or conjugate thereof and immune checkpoint inhibitor ... |
|
|
Invention
|
Pharmaceutical composition for preventing or treating cancer including interleukin 2 analog or co... |
|
2023
|
Invention
|
Novel triple activator having activity on all of glp-1, gip, and glucagon receptors, and pharmace... |
|
|
Invention
|
Pharmaceutical composition for preventing or treating graft-versus-host disease containing glp-2 ... |
|
|
Invention
|
Antigenic peptide having multiple kras variant peptides linked thereto, nucleic acid encoding the... |
|
|
Invention
|
Formulation containing immunoactive interleukin 2 analog conjugate. The present invention relates... |
|
|
Invention
|
Novel crystalline form of a pyrimidine compound and pharmaceutical compositions comprising the sa... |
|
|
Invention
|
Novel pyrimidine derivative as bruton's tyrosine kinase inhibitor. The present disclosure relates... |
|
|
Invention
|
Novel glp-1 receptor antagonist, and pharmaceutical composition for preventing or treating congen... |
|
|
Invention
|
Novel tricyclic derivative compound and uses thereof. The present invention relates to a novel tr... |
|
|
Invention
|
Novel heterobicyclic compound for inhibiting yap-tead interaction and pharmaceutical composition ... |
|
|
Invention
|
Novel tricyclic heterocyclic carbaldehyde compound and pharmaceutical composition, containing sam... |
|
|
Invention
|
Immunostimulating il-2 analogs.
Modifications to interleukin-2 alpha receptors are disclosed. In... |
|
|
Invention
|
Methods of treating neutorpenia using g-csf protein complex.
This disclosure provides a method o... |
|
|
Invention
|
Combination therapy of glp-2 with insulinotropic peptide, tnfα inhibitor or both for preventing o... |
|
|
Invention
|
Pharmaceutical composition comprising acetylsalicylic acid and proton pump inhibitor. The present... |
|
2022
|
Invention
|
Therapeutically effective combination of a flt3 inhibitor and a bcl-2 inhibitor for the treatment... |
|
|
Invention
|
Composition for orally administered formulation containing glp-1 analogue.
A composition, suitab... |
|
|
Invention
|
Therapeutic use of combination including triple agonist having activities to all of glucagon, glp... |
|
|
Invention
|
Oral complex tablet comprising sitagliptin, dapagliflozin, and metformin.
An oral dosage form in... |
|
|
Invention
|
Non-natural 5'-untranslated region and 3'-untranslated region and use thereof.
Provided is an is... |
|
|
Invention
|
Efpeglenatide to reduce risk of developing cardiovascular disease or renal dysfunction.
Provided... |
|
|
Invention
|
Pharmaceutical composition for preventing or treating chronic renal disease including glucagon de... |
|
|
Invention
|
Combination therapy with a raf inhibitor and a pd-1 axis inhibitor.
A combination therapy compri... |
|
|
Invention
|
Combination therapy with belvarafenib and cobimetinib or with belvarafenib, cobimetinib, and atez... |
|
|
Invention
|
Novel conjugate of immune-stimulating il-2 analog and preparation method thereof.
The present in... |
|
|
Invention
|
Belvarafenib for use in treatment of brain cancers.
Provided are methods for the use of belvaraf... |
|
|
Invention
|
Liquid formulation of protein and methods of preparing the same.
Provided are a liquid formulati... |
|
2021
|
Invention
|
Combination therapy of insulinotropic peptide and glp-2, for preventing or treating short bowel s... |
|
|
Invention
|
Novel triple agonist having activities on all of glucagon, glp-1, and gip receptors and use there... |
|
|
Invention
|
Use of therapeutic enzyme fusion protein in prevention and treatment of neuropathy caused by or a... |
|
|
Invention
|
Use of therapeutic enzyme fusion protein in prevention and treatment of renal diseases caused by ... |
|
|
Invention
|
Use of trigonal agonist having activities to all of glucagon, glp-1, and gip receptors in treatme... |
|
|
Invention
|
Pharmaceutical composition for preventing or treating lupus-related diseases comprising gip deriv... |
|
|
Invention
|
Pharmaceutical composition comprising glucagon/glp-1/gip triple agonist or long-acting conjugate ... |
|
|
Invention
|
Gip derivative, long-acting conjugate thereof, and pharmaceutical composition comprising same.
P... |
|
|
Invention
|
Glp-1/gip dual agonist, long-acting conjugate thereof, and pharmaceutical composition comprising ... |
|
|
Invention
|
Therapeutic use of long-acting conjugate of triple agonist acting on all of glucagon, glp-1 and g... |
|
|
Invention
|
Therapeutic use, for neurodegenerative diseases, of triple agonist having activity with respect t... |
|
|
Invention
|
Pharmaceutical composition for preventing or treating bone diseases, comprising triple agonist or... |
|
|
Invention
|
Polyethylene glycol derivative, composition comprising same, and method for preparing bioactive p... |
|
|
Invention
|
Hypotensive pharmaceutical composition comprising triple activator having activity for all of glu... |
|
|
Invention
|
Pharmaceutical composition comprising long-acting conjugate of triple glucagon/glp-1/gip receptor... |
|
|
Invention
|
Therapeutic use of combination comprising triple agonistic long-acting conjugate or triple agonis... |
|
|
Invention
|
Therapeutic use of glucagon derivative or conjugate thereof for liver disease.
New therapeutic u... |
|
2020
|
Invention
|
Pharmaceutical composition comprising proton pump inhibitor and antacid.
One aspect provides a p... |
